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 ABSTRACT 
Introduction and Aims: Illicitly-manufactured fentanyl continues to fuel the opioid 
overdose crisis throughout the United States and Canada. However, little is known about 
factors associated with knowingly or unknowingly using fentanyl. Therefore, we sought 
to identify the prevalence and correlates of suspected/known and unknown exposure to 
fentanyl (excluding the prescribed one) among people who inject drugs (PWID), 
including associated overdose risks. 
 
Design and Methods: Data were derived from three prospective cohort studies of 
community-recruited people who use drugs in Vancouver, Canada in 2016–2017. 
Multivariable logistic regression was used to identify correlates of suspected/known 
exposure (i.e., urine drug screen positive [UDS+] and self-reporting past three-day 
exposure) and unknown exposure to fentanyl (i.e., UDS+ and self-reporting no past three-
day exposure), respectively. 
 
Results: Among 590 PWID, 296 (50.2%) tested positive for fentanyl. Of those, 143 (48.3%) 
had suspected/known and 153 (51.7%) had unknown exposure to fentanyl. In 
multivariable analyses, using supervised injection sites and possessing naloxone were 
associated with both suspected/known and unknown exposure (all p<0.05). Injecting 
drugs alone (Adjusted Odds Ratio [AOR]: 3.26; 95% Confidence Interval [CI]: 1.72–6.16) 
was associated with known exposure, but not with unknown exposure. 
 
Discussion and Conclusions: We found a high prevalence of fentanyl exposure in our 
sample of PWID, with one half of those exposed consuming fentanyl unknowingly. While 
those exposed to fentanyl appeared more likely to utilize some overdose prevention 
services, PWID with suspected/known fentanyl exposure were more likely to inject alone, 
indicating a need for additional overdose prevention efforts for this group. 
 
Word count: 249 (max. 250 words) 
 
Key words: fentanyl, opioids, injection drug use, overdose, epidemiology, harm reduction  
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INTRODUCTION 
 In recent years, there has been an exponential growth in the number of fatal drug 
overdoses throughout the United States and Canada [1–3]. The Canadian province of 
British Columbia (BC) experienced a rapid rise in opioid overdoses earlier than many 
other jurisdictions in North America, with drug overdose mortality rates in 2017 being 
two- to three-fold higher compared to national averages in Canada and the United States 
[2,4]. A recent study also estimated that between 2014 and 2016, life expectancy at birth 
in the province declined by 0.12 years due to drug overdose deaths alone [5]. While a 
public health emergency was declared in April 2016 [6], and a range of overdose 
prevention interventions have been implemented since then [7], the province continues 
to see high numbers of fatal overdoses, though showing some declining trends in 2019 
[3]. 
The key contributor to the overdose crisis is illicitly-manufactured fentanyl (a 
potent synthetic opioid) and its analogues that have contaminated the illicit drug supply 
[8,9]. In BC, fentanyl has been attributed to the dramatic increase in overdose mortality 
since 2012, with fentanyl-detection rates in illicit drug overdose deaths increasing from 
4% in 2012 to 86% in 2018 [10]. Fentanyl is commonly added to or sold as heroin [9,11,12], 
though other street drugs in the unregulated market, including stimulants and 
counterfeit medications (e.g., benzodiazepine pills), have also been found to contain 
fentanyl [13,14]. Previous studies reported that people who use drugs struggle to discern 
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substances sold as heroin and may be unknowingly exposed to fentanyl [11,15]. A recent 
qualitative study in Vancouver, BC [16] reported that people who use illicit drugs 
generally had a high level of trust for their regular drug dealers, who they believed would 
provide them with accurate information regarding the contents of the drug sold (e.g., 
whether the drug is cut with fentanyl). However, the extent to which street-level drug 
dealers possess and convey accurate information on the contents of the drug to their 
clients is not known. People may also obtain drugs from unfamiliar sources from time to 
time, and therefore may not always be aware of the contents of the drug they obtain [16].  
As fentanyl has increasingly contaminated the illicit drug supply, previous studies 
also reported that some people who use drugs have adapted their drug-using practices 
in an effort to prevent an overdose, including reducing the frequency of drug use, using 
drugs with others, and carrying naloxone [17]. A recent cross-sectional study from three 
cities in the US reported that approximately 60% of their community-recruited sample of 
people who use illicit drugs (n=334) had ever suspected fentanyl exposure prior to using 
their drugs, and the prevalence of engaging in some harm reduction behaviour (e.g., 
using less of the drug) among those with suspected fentanyl exposure was relatively high 
at 39% [18]. However, since the self-report data were not corroborated with biological 
markers of fentanyl exposure, the extent to which those individuals accurately identified 
their exposure to fentanyl was unknown.  
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While knowledge of fentanyl exposure may be an important factor influencing 
individuals’ drug-using behaviour, potential differences in overdose risks associated 
with known and unknown exposure to fentanyl have not been fully characterized, 
particularly among people who inject drugs (PWID). A recent survey of 486 people who 
use drugs across BC documented that about 60% had been recently exposed to fentanyl, 
with 64% of them reporting known exposure to fentanyl [19]. This study found that those 
who preferred injection to non-injection drug use were more likely to report known 
exposure to fentanyl [19]. Building on this previous study and considering that PWID is 
the population that suffers from extremely high mortality from drug overdoses [20,21], it 
is important to characterize overdose risks associated with known and unknown 
exposure to fentanyl among PWID. Therefore, we sought to estimate the prevalence and 
correlates (including overdose risk behaviour) of suspected/known and unknown 
exposure to fentanyl (excluding the prescribed one) among PWID in Vancouver.  
 
METHODS 
Study setting and design  
Data were derived from three ongoing prospective cohort studies of people who 
use drugs in Vancouver: the Vancouver Injection Drug Users Study (VIDUS), the AIDS 
Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the At-Risk Youth 
Study (ARYS). Detailed descriptions of these cohorts have been previously published 
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elsewhere [22,23]. In brief, VIDUS enrols HIV-seronegative adults (≥18 years of age) who 
injected illicit drugs in the month prior to enrolment. ACCESS enrols HIV-seropositive 
adults who used an illicit drug in the month prior to enrolment, and ARYS enrols street-
involved youth aged 14 to 26 who used an illicit drug in the month prior to enrolment. 
The cohorts use harmonized data collection procedures to allow for pooled.  
At baseline and semi-annually thereafter, participants complete an interviewer-
administered questionnaire, which elicits a range of information including demographic 
data, substance use, and healthcare access. Since June 2016, a multi-panel qualitative 
urine drug screen (UDS) using BTNX Rapid ResponseTM Multi-Drug Test Panel 
(Markham, ON, Canada) has been added to the data collection procedures. This rapid 
chromatographic immunoassay qualitatively and simultaneously detected multiple 
substances in urine within five minutes. As described previously [24], the screened 
substances (calibrator, cut-off value in ng/mL) included: fentanyl (fentanyl, 100, and 
norfentanyl, 20); morphine/heroin (morphine, 100); methadone metabolite (2-Ethylidine-
1, 5-dimethyl-3, 3-diphenylpyrrolidine, 100); buprenorphine (BUP-3-D-Glucoronide, 10); 
cocaine (benzoylecgonine, 150); amphetamine/methamphetamine (d-amphetamine, 
1000); benzodiazepine (oxazepam, 300). The UDS kit has separate panel strips for each 
substance. If only one coloured line appears on the strip, it means that it tested positive 
for the substance. Two lines on the strip indicate a negative result. If no line appears on 
the strip, the UDS is invalid. While detection times after use of these substances vary 
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depending on many factors, including routes of administration, frequencies of use, and 
doses, the BTNX fentanyl test panel with the aforementioned cut-off values is believed to 
detect exposure to fentanyl within a maximum of past three days [25]. All three cohorts 
have received approvals from the University of British Columbia/Providence Health Care 
Research Ethics Board.  
Study sample and measures  
Eligibility criteria for the present cross-sectional study included: completing both 
the interviewer-administered questionnaire and UDS between December 2016 and May 
2017, and reporting having injected illicit drugs in the past six months. Additional sample 
restrictions were made based on the combinations of the UDS and self-report data that 
were used to derive the primary outcome as described below. 
The primary outcome was recent exposure to fentanyl (excluding the prescribed 
one), which was classified as suspected/known exposure vs. unknown exposure vs. no 
exposure. Specifically, we defined suspected/known exposure as having a positive UDS 
result for fentanyl and self-reporting suspected exposure to fentanyl in the past three 
days. Suspected exposure to fentanyl was ascertained from a question: “Have you used 
any drugs that you knew or now believe contained fentanyl? If yes, when was the last 
time you used such drugs?” In this question, fentanyl referred to non-prescribed fentanyl 
only. Trained interviewers asked this question either before administering the UDS or 
without showing or corroborating the results of UDS if UDS had been administered 
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before the interview, in order to avoid reporting bias. Unknown exposure to fentanyl was 
defined as having a positive UDS result for fentanyl and self-reporting no suspected 
exposure to fentanyl in the past three days. Two participants who were classified as 
unknown fentanyl exposure but self-reported use of prescribed fentanyl in the last 24 
hours were excluded from the analytic sample in order to ensure that this category only 
includes cases of unknown exposure to non-prescribed fentanyl. No exposure to fentanyl 
was defined as having a negative UDS result for fentanyl. Among 335 individuals who 
tested negative for fentanyl, 42 (12.2%) reported suspected exposure to fentanyl in the 
past three days and were excluded from the analysis. Determination of the analytic study 
sample is further described in Figure 1. 
 In order to identify potentially distinct patterns of recent substance use among the 
three groups of the primary outcome measure, we examined UDS results of six 
substances (i.e., morphine, methadone metabolite, buprenorphine, cocaine, 
amphetamine/methamphetamine and benzodiazepine) as well as self-reported patterns 
of use for eight substance over the past three days, including heroin, non-medical use of 
prescription opioids (POs), cocaine, crack cocaine, crystal methamphetamine, speedball 
(i.e., combining an opioid and cocaine) or goofball (i.e., combining an opioid and crystal 
methamphetamine) injection, exclusive use of stimulants (i.e., either cocaine, crack 
cocaine or crystal methamphetamine, but no opioids), and benzodiazepine (non-medical 
use). Non-medical use of POs was defined as using POs when they were not prescribed 
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for the participant or that the participant took only for the experience or feeling they 
caused. 
We also considered a range of factors that we hypothesized might be associated 
with suspected/known and unknown exposure to fentanyl based on previous studies 
[19,24,26]. Demographic variables included: age (continuous, per year older); sex (female 
vs. male); and ethnicity/ancestry (white vs. non-white). For behavioural and social-
structural factors, we considered patterns reported in the past six months unless 
otherwise specified because most of the relevant questions in the questionnaire referred 
to the past six months. Substance use-related variables included: ³ daily heroin injection, 
³ daily non-medical use of PO, ³ daily cocaine injection, ³ daily crack smoking, ³ daily 
crystal methamphetamine use (either injection or non-injection), ³ daily alcohol use, and 
non-medical use of benzodiazepine. Variables related to overdose risks and prevention 
included: experiencing a non-fatal overdose (defined as having a negative reaction from 
using too much drugs by accident); injecting alone; being enrolled in opioid agonist 
therapy (OAT); using a supervised injection/overdose prevention site; and currently 
possessing naloxone. Social and structural exposures in the past six months included: 
residence in the Downtown Eastside (DTES) neighbourhood in Vancouver, an area with 
a large open drug market; being homeless; recent incarceration; and inability to access 
any community health or social services (e.g., food services, housing, counsellor, social 
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worker), defined as reporting having been unable to access any of these services when 
they wanted. Unless otherwise stated, all variables were dichotomized as yes vs. no. 
Statistical analyses 
As a first step, we examined the sample characteristics stratified by recent 
exposure to fentanyl, using the Pearson’s Chi-squared test (for categorical variables) and 
Kruskal-Wallis test (for continuous variables). Next, in order to identify a set of factors 
associated with higher odds of suspected/known and unknown exposure to fentanyl, 
respectively, we built two multivariable logistic regression models: Model 1 compared 
suspected/known vs. no exposure to fentanyl, and Model 2 compared unknown vs. no 
exposure to fentanyl. In addition, we fit Model 3 to compare suspected/known vs. 
unknown exposure to fentanyl. Because of highly skewed distributions (see Table 1), the 
variables of ³ daily heroin injection and ³ daily non-medical use of PO were removed 
from the multivariable modelling procedure for each model. For all models, we used an 
a priori-defined backward model selection procedure based on examination of Akaike 
Information Criterion (AIC) to fit a multivariable model [27]. In brief, we constructed a 
full model including all variables that were associated with the outcome at p<0.10 in 
bivariable analyses. After examining the AIC of the model, we removed the variable with 
the largest p-value and built a reduced model. We continued this iterative process until 
we reached the lowest AIC score. All p-values were two-sided. All statistical analyses 
were performed using SAS 9.4 (Cary, North Carolina, USA). 





In total, 590 participants were eligible for the present study. As shown in Table 1, 
225 (38%) were female, 323 (55%) self-identified as white, and the median age was 46 
(quartile [Q] 1–3: 35–54) years. A total of 296 (50%) individuals tested positive for 
fentanyl, of whom 143 (48%) had suspected/known and 153 (52%) had unknown 
exposure to fentanyl.  
Regarding the self-reported substance use in the past three days (see Table 1), there 
was a significantly higher prevalence of reported stimulant use but no opioid use among 
those who were not exposed to fentanyl (49%) when compared to those with 
suspected/known and unknown exposure to fentanyl (0.7% and 12%) (p<0.001). 
However, crystal methamphetamine use was the highest among those with 
suspected/known exposure to fentanyl (49%), followed by those with unknown exposure 
(39%) and no exposure to fentanyl (34%) (p=0.008). The prevalence of reporting speedball 
or goofball injection followed a similar pattern.  
Also shown in Table 1, the UDS results of the six substances were similar to the 
findings on self-reported substance use in the past three days. Specifically, the prevalence 
of positive UDS results for morphine was significantly higher among those with known 
and unknown exposure to fentanyl (94% and 86%) compared to those with no exposure 
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to fentanyl (26%) (p<0.001). The prevalence of positive UDS results for amphetamine was 
the highest among those with suspected/known exposure to fentanyl (70%), followed by 
those with unknown exposure (55%) and no exposure to fentanyl (39%) (p<0.001).  
Table 2 lists the top five combinations of positive UDS results identified among 
those with suspected/known and unknown exposure to fentanyl, respectively, 
accounting for approximately a half of each sub-sample. As shown, among those with 
suspected/known exposure to fentanyl, all combinations included both morphine and 
one of the stimulants (amphetamine or cocaine), as did all but one combination 
(methadone metabolite and morphine) among those with unknown exposure to fentanyl.  
Factors associated with suspected/known and unknown exposure to fentanyl 
Table 3 presents the results of bivariable and multivariable logistic regression 
analyses. As shown, in both Model 1 (comparing suspected/known vs. no exposure to 
fentanyl) and Model 2 (comparing unknown vs. no exposure to fentanyl), younger age, 
OAT use, use of supervised injection/overdose prevention sites, and possession of 
naloxone were independently and positively associated with both suspected/known and 
unknown fentanyl exposure (all p<0.05). DTES residence (adjusted odds ratio [AOR]:  
2.00; 95% confidence interval [CI]: 1.18, 3.39), incarceration (AOR: 3.21; 95% CI: 1.22, 8.46), 
self-reported inability to access to any community health or social services (AOR: 1.83; 
95% CI: 1.08, 3.11), non-fatal overdose (AOR: 2.01; 95% CI: 1.14, 3.54), and injecting alone 
(AOR: 3.26; 95% CI: 1.72, 6.16) were independently and positively associated with 
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suspected/known exposure to fentanyl, but not with unknown exposure to fentanyl. In 
Model 3 (comparing suspected/known vs. unknown exposure to fentanyl), injecting alone 
was independently and positively associated with suspected/known exposure (AOR: 
3.77; 95% CI: 2.04, 6.99).  
 
DISCUSSION 
 We found that approximately one-half of our community-recruited sample of 
PWID in Vancouver tested positive for fentanyl, and one-half of these individuals 
reported being unknowingly exposed to fentanyl. Combined data from UDS and self-
reported use of drugs indicated that polysubstance use, most commonly involving illicit 
opioids and crystal methamphetamine, was prevalent among those exposed to fentanyl, 
particularly among those with suspected/known exposure. In multivariable analyses, 
PWID who had recent exposure to fentanyl were more likely to be younger, on OAT, use 
supervised consumption sites, and carry naloxone regardless of being aware or unaware 
of fentanyl exposure. Those who suspected their fentanyl exposure were additionally 
more likely to have recently injected drugs alone, experienced a non-fatal overdose, been 
incarcerated, and been unable to access health or social services. When comparing PWID 
who were and were not aware of fentanyl exposure, injecting alone was the only factor 
that remained independently associated with suspected/known exposure to fentanyl. 
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 We found a high prevalence of polysubstance use involving illicit opioids and 
crystal methamphetamine among those with fentanyl exposure, and the prevalence of 
the past three-day use of crystal methamphetamine was the highest (nearly 50%) among 
those with suspected/known fentanyl exposure. This is in line with recent reports 
documenting increasing trends in co-detection of fentanyl and methamphetamine in fatal 
drug overdose cases in the US [28] and BC [29]. Specifically, in BC, there has been a five-
fold increase in the number of illicit drug toxicity deaths involving crystal 
methamphetamine since 2014, the majority (87%) of which also involved fentanyl [29]. 
Similarly, several studies in the US have also suggested a marked increase in 
methamphetamine use among people who use opioids in recent years [30–34]. 
Qualitative data in an online survey suggested that there might be a range of factors 
motivating people who use opioids to use methamphetamine, including high-seeking, 
balancing the effect of opioids, and its easy availability as a substitute for opioids [33]. 
However, in our multivariable regression analyses, at least daily use of crystal 
methamphetamine was not significantly associated with either suspected/known or 
unknown exposure to fentanyl, indicating that those exposed to fentanyl may be 
engaging in less frequent use of crystal methamphetamine. Future research should 
investigate motivations for, practices and effects of co-use of street opioids and crystal 
methamphetamine in more depth.  
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 The significant association between non-fatal overdose and suspected/known 
fentanyl exposure could have two possible interpretations. It may be that those 
individuals with suspected/known fentanyl exposure are simply at a higher risk of 
overdose. Alternatively, because of the way suspected/known fentanyl exposure was 
ascertained, it may be that some of those with suspected/known fentanyl exposure might 
have not necessarily been aware of their fentanyl exposure at the time of their drug use 
but became aware after they experienced a non-fatal overdose in the past three days. 
However, unfortunately, our dataset did not allow us to determine how many of the 46 
(32% of the suspected/known fentanyl exposure group) individuals reporting both 
suspected fentanyl exposure in the past three days and non-fatal overdose in the past six 
months fell into such cases.  
 Of concern, those who engaged in overdose risk behaviour (i.e., injecting alone) 
were more likely to report suspected/known exposure to fentanyl. Such behaviour was 
not as salient among individuals with unknown fentanyl exposure. These findings may 
suggest that this sub-population of PWID with suspected/known exposure to fentanyl 
might be at a particularly high risk of experiencing a fatal overdose. While future research 
needs to establish the temporal relationship between injecting alone and known fentanyl 
exposure, given the well-known highly toxic illicit drug supply in our study setting [35], 
it may be that some PWID were injecting alone despite knowingly using drugs that 
contained fentanyl. In this regard, a large body of literature on HIV/AIDS demonstrates 
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that individual-level education about HIV risk behaviour (e.g., syringe sharing) alone 
would not be sufficient to enable PWID to avoid HIV risk behaviour unless broader social 
and structural factors that shape risk environments and constrain PWID’s ability to 
exercise harm reduction practices are addressed [36]. A recent rapid ethnographic study 
from our study setting also reported that some women who use drugs do not utilize 
housing-based overdose prevention sites (i.e., supervised consumption sites) and 
intentionally used drugs alone at their home as they considered those overdose 
prevention sites to be unsafe environments [37].  Taken together, there is an urgent need 
to understand why some PWID inject alone and address the fatal overdose risk associated 
with this behaviour.        
 Further, while PWID exposed to fentanyl appeared more likely to access some key 
overdose prevention services such as supervised consumptions sites, naloxone and OAT, 
those who were aware of fentanyl exposure were more likely to have recently been 
incarcerated and report inability to access health/social services. These markers of 
overdose risk and structural vulnerability did not stand out among PWID with unknown 
exposure to fentanyl. Collectively, our findings suggest that those with suspected/known 
exposure to fentanyl may be the ones who particularly suffer from marginalization and 
bear the greatest overdose risks. Therefore, our study findings indicate a need for 
structural interventions to address the upstream drivers of overdose risk, in addition to 
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individual-level overdose prevention interventions that have been the primary responses 
to the ongoing opioid overdose crisis in the United States and Canada to date.  
 This study has some limitations. First, the cross-reactivity of the UDS may have 
resulted in over- or underestimation of the recent exposure to some substances [38], 
although a previous study documented that the UDS panel used in the present study had 
high specificity and sensitivity for fentanyl detection [39]. Also, our UDS panel did not 
screen 6-monoacetylmorphine (a specific metabolite of heroin) or fentanyl analogues 
such as carfentanil. Second, self-reported data may be influenced by some reporting bias, 
although such data have been shown to be mostly valid in studies involving PWID [40]. 
Third, a non-random sample used in the present study limits the generalizability of our 
findings.  
In sum, we found that a half of PWID in our sample tested positive for fentanyl, 
with a half of these individuals being unknowingly exposed to fentanyl. Co-use of illicit 
opioids and crystal methamphetamine appeared highly prevalent among those exposed 
to fentanyl, particularly those with suspected/known exposure. While those exposed to 
fentanyl were more likely to access some key overdose prevention services, those who 
were aware of fentanyl exposure were also more likely to inject drugs alone, experience 
recent incarceration and report inability to access health or social services, indicating that 
this sub-population of PWID may be particularly marginalized and at a high risk of fatal 
overdose. These findings indicate a need for scaling up ongoing overdose prevention 
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efforts by addressing not only opioid use but also stimulant use, and the social and 
structural factors that shape overdose risk behaviour among this population.  
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Table 1: Sample characteristics stratified by exposure to fentanyl among 590 PWID in Vancouver, Canada, 2016-2017. 
Characteristic 









Age (median, Q1-Q3) 45.7 (34.6 – 53.7) 38.6 (30.9 – 49.2) 43.3 (34.7 – 50.6) 49.3 (38.9 – 55.4) <0.001c 
Female 225 (38%) 60 (42%) 65 (42%) 100 (34%) 0.129 
White 323 (55%) 82 (57%) 85 (56%) 156 (53%) 0.682 
DTES residencea 403 (68%) 106 (74%) 112 (73%) 185 (63%) 0.020 
Homelessa 109 (18%) 38 (27%) 29 (19%) 42 (14%) 0.008 
Incarcerationa 40 (7%) 19 (13%) 13 (9%) 8 (3%) <0.001 
Inability to access any community 
health or social servicesa 
143 (24%) 44 (31%) 39 (26%) 60 (20%) 0.058 
Non-fatal overdosea 127 (22%) 46 (32%) 36 (24%) 45 (15%) <0.001 
Injecting alonea 436 (74%) 126 (88%) 101 (66%) 209 (71%) <0.001 
Opioid agonist therapya 360 (61%) 99 (69%) 102 (67%) 159 (54%) 0.002 
Supervised injection/overdose 
prevention sites usea 
283 (48%) 91 (64%) 85 (56%) 107 (36%) <0.001 
Currently possessing naloxone 397 (67%) 106 (74%) 117 (77%) 174 (59%) <0.001 
Self-reported substance use in the past 6 monthsa     
  ³ Daily heroin injectiona, b 182 (31%) 100 (70%) 67 (44%) 15 (5%) <0.001 
  ³ Daily non-medical PO usea 19 (3%) 9 (6%) 2 (1%) 8 (3%) 0.050d 
  ³ Daily cocaine injectiona 33 (6%) 8 (6%) 5 (3%) 20 (7%) 0.304 
  ³ Daily crack smokinga 42 (7%) 11 (8%) 13 (9%) 18 (6.1%) 0.621 
  ³ Daily crystal methamphetamine usea 112 (19%) 34 (24%) 29 (19%) 49 (17%) 0.206 
  ³ Daily alcohol usea 44 (7%) 5 (4%) 15 (10%) 24 (8%) 0.096 
  Non-medical use of  benzodiazepinea 36 (6%) 9 (6%) 8 (5%) 19 (7%) 0.870 
Self-reported substance use in the past 3 days     
  Heroin 285 (48%) 132 (92%) 110 (72%) 43 (15%) <0.001 
Awareness of fentanyl exposure 
 26 
  Non-medical use of PO 41 (7%) 16 (11%) 7 (5%) 18 (6%) 0.060 
  Cocaine 88 (15%) 18 (13%) 17 (11%) 53 (18%) 0.100 
  Crack cocaine 108 (18%) 20 (14%) 28 (18%) 60 (20%) 0.265 
  Crystal methamphetamine 229 (39%) 70 (49%) 60 (39%) 99 (34%) 0.008 
  Speedball or goofball injection 74 (13%) 34 (24%) 28 (18%) 12 (4%) <0.001 
  Using stimulants but no opioidsb 162 (27%) 1 (1%) 18 (12%) 143 (49%) <0.001d 
  Non-medical use of benzodiazepine 13 (2%) 4 (3%) 3 (2%) 6 (2%) 0.873d 
UDS positive for:      
  Morphine 343 (58%) 135 (94%) 131 (86%) 77 (26%) <0.001 
  Methadone metabolite 318 (54%) 83 (58%) 96 (63%) 139 (47%) 0.004 
  Buprenorphine 34 (6%) 7 (5%) 6 (4%) 21 (7%) 0.336 
  Cocaine 313 (53%) 73 (51%) 95 (62%) 145 (49%) 0.032 
  Amphetamine 299 (51%) 100 (70%) 84 (55%) 115 (39%) <0.001 
  Benzodiazepine 118 (20%) 42 (29%) 26 (17%) 50 (17%) 0.006 
Cohort designation     0.022 
  VIDUS 302 (51%) 79 (55%) 76 (50%) 147 (50%)  
  ACCESS 204 (35%) 35 (25%) 56 (36%) 113 (38%)  
  ARYS 84 (14%) 29 (20%) 21 (14%) 34 (12%)  
ACCESS: AIDS Care Cohort to evaluate Exposure to Survival Services. ARYS: At-Risk Youth Study. DTES: Downtown Eastside. PO: 
prescription opioid. PWID: people who inject drugs. Q: quartile. UDS: urine drug screen. VIDUS: Vancouver Injection Drug Users Study. 
a Denotes behaviors/events in the past six months. 
b Stimulants include any of cocaine, crack cocaine or crystal methamphetamine. 
c Denotes that p-value was obtained from the Kruskal-Wallis test. 
d Denotes that p-value was obtained from the Fisher’s exact test. 
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Table 2: The top five combinations of positive UDS results among PWID with suspected/known and unknown exposure 
to fentanyl in Vancouver, Canada, 2016-2017. 
Combination n % 
Among PWID with suspected/known exposure to fentanyl (n = 143)   
Amphetamine + Methadone metabolite + Morphine 23 16 
Amphetamine + Cocaine + Methadone metabolite + Morphine 17 12 
Amphetamine + Morphine 14 10 
Amphetamine + Cocaine + Morphine 10 7 
Cocaine + Methadone metabolite + Morphine 9 6 
Among PWID with unknown exposure to fentanyl (n = 155)   
Amphetamine + Cocaine + Methadone metabolite + Morphine 26 17 
Cocaine + Methadone metabolite + Morphine 21 14 
Amphetamine + Morphine 15 10 
Methadone metabolite + Morphine 13 8 
Amphetamine + Methadone metabolite + Morphine 12 8 
PWID: people who inject drugs. UDS: urine drug screen.    
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Table 3: Bivariable and multivariable logistic regression analyses of factors associated with suspected/known and unknown exposure to fentanyl 
among 590 PWID in Vancouver, Canada, 2016-2017. 
Variable 
Model 1  
(Suspected/Known vs. no exposure)  
Model 2  
(Unknown vs. no exposure)  
Model 3  








































0.105   1.42 
(0.95, 2.12) 
0.088   0.99 
(0.62, 1.57) 
0.968   
White 1.19 
(0.80, 1.78) 
0.399   1.11 
(0.75, 1.64) 
0.616   1.08 
(0.68, 1.70) 
0.757   










0.857   
Homelessa 2.17 
(1.32, 3.56) 
0.002   1.40 
(0.83, 2.36) 
0.201   1.55 
(0.89, 2.68) 











0.188   
Inability to access any 







0.227   1.30 
(0.78, 2.16) 
0.313   


































0.637   
Supervised 
injection/overdose 
























0.640   
Self-reported substance use in the past 6 monthsa         
  ³ Daily cocaine injectiona 0.81 
(0.35, 1.89) 
0.629   0.46 
(0.17, 1.26) 
0.131   1.75 
(0.56, 5.49) 
0.335   
  ³ Daily crack smokinga 1.28 
(0.59, 2.78) 
0.537   1.42 
(0.68, 2.99) 
0.351   0.90 
(0.39, 2.07) 
0.801   




0.077   1.17 
(0.70, 1.94) 
0.546   1.33 
(0.76, 2.33) 
0.312   
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0.946   0.80 
(0.34, 1.87) 
0.604   1.22 
(0.46, 3.25) 
0.694   
Cohort designation             
  ACCESS (vs. VIDUS) 0.58 
(0.36, 0.92) 
0.021   0.96 
(0.63, 1.46) 
0.845   0.60 (0.36, 
1.02) 
0.058   
  ARYS (vs. VIDUS) 1.59 
(0.90, 2.80) 
0.110   1.19 
(0.65, 2.20) 
0.568   1.33 (0.70, 
2.53) 
0.387   
ACCESS: AIDS Care Cohort to evaluate Exposure to Survival Services. AOR: adjusted odds ratio. ARYS: At-Risk Youth Study. CI: confidence interval. DTES: Downtown 
Eastside. OR: odds ratio. PO: prescription opioid. PWID: people who inject drugs. VIDUS: Vancouver Injection Drug Users Study. 
a Denotes behaviors/events in the past six months. 
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Figure 1: Determination of the analytic sample. 
 
UDS: urine drug screen. 
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